Full metadata record
DC Field | Value | Language |
---|---|---|
dc.creator | Abajo, A. (Ana) | - |
dc.creator | Boni, V. (Valentina) | - |
dc.creator | Lopez, I. (Inés) | - |
dc.creator | Gonzalez-Huarriz, M. (Marisol) | - |
dc.creator | Bitarte, N. (Nerea) | - |
dc.creator | Rodriguez, J. (Javier) | - |
dc.creator | Zarate, R. (Ruth) | - |
dc.creator | Bandres, E. (Eva) | - |
dc.creator | Garcia-Foncillas, J. (Jesús) | - |
dc.date.accessioned | 2014-07-17T10:08:15Z | - |
dc.date.available | 2014-07-17T10:08:15Z | - |
dc.date.issued | 2012-07-10 | - |
dc.identifier.citation | Abajo A, Boni V, Lopez I, Gonzalez-Huarriz M, Bitarte N, Rodriguez J, et al. Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients. Br J Cancer. 2012 Jul 10;107(2):287-290. | es_ES |
dc.identifier.issn | 0007-0920 | - |
dc.identifier.uri | https://hdl.handle.net/10171/36169 | - |
dc.description.abstract | BACKGROUND: To identify whether circulating levels of angiogenesis-related factors may be predictive of bevacizumab efficacy in pre-treated metastatic colorectal cancer (mCRC) patients. METHODS: Pre-treatment serum levels of 24 cytokines were measured using a multiplex bead assay (MBA) in 32 pre-treated mCRC patients treated with irinotecan plus bevacizumab-based salvage therapy. Macrophage-derived chemokine (MDC), interleukins (ILs) 8 and 6 levels were also validated by enzyme-linked immunosorbent assay (ELISA) at different time points during therapy. RESULTS: Higher epidermal growth factor (EGF) and MDC baseline levels (2.2- and 1.4-fold, respectively) and lower IL-10, IL-6 and IL-8 levels (0.2-, 0.6-, and 0.6-fold, respectively, P<0.05) were observed in patients responding to therapy. Baseline levels of these five serum factors compose a risk signature that may define the subset of patients most likely to benefit from bevacizumab-based therapy in terms of response rate and survival times. A positive correlation was found between MBA and ELISA results (P<0.01). Treatment exposure increased MDC and had opposite effects on IL-8 levels, which were decreased (P<0.05). CONCLUSION: This study suggests that a set of inflammatory and angiogenesis-related serum markers may be associated with the efficacy of bevacizumab-containing regimen. | es_ES |
dc.language.iso | eng | es_ES |
dc.publisher | Nature | es_ES |
dc.rights | info:eu-repo/semantics/openAccess | es_ES |
dc.subject | Bevacizumab | es_ES |
dc.subject | Serum biomarkers | es_ES |
dc.subject | Colorectal cancer | es_ES |
dc.subject | Multiplex bead assays | es_ES |
dc.title | Identification of predictive circulating biomarkers of bevacizumab-containing regimen efficacy in pre-treated metastatic colorectal cancer patients | es_ES |
dc.type | info:eu-repo/semantics/article | es_ES |
dc.identifier.doi | http://dx.doi.org/10.1038/bjc.2012.242 | es_ES |
Files in This Item:
Statistics and impact
Items in Dadun are protected by copyright, with all rights reserved, unless otherwise indicated.